[go: up one dir, main page]

GB201608587D0 - Treatment of opiod tolerance - Google Patents

Treatment of opiod tolerance

Info

Publication number
GB201608587D0
GB201608587D0 GBGB1608587.0A GB201608587A GB201608587D0 GB 201608587 D0 GB201608587 D0 GB 201608587D0 GB 201608587 A GB201608587 A GB 201608587A GB 201608587 D0 GB201608587 D0 GB 201608587D0
Authority
GB
United Kingdom
Prior art keywords
treatment
opiod
tolerance
opiod tolerance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1608587.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Dundee
Original Assignee
University of Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Dundee filed Critical University of Dundee
Priority to GBGB1608587.0A priority Critical patent/GB201608587D0/en
Publication of GB201608587D0 publication Critical patent/GB201608587D0/en
Priority to PCT/GB2017/051361 priority patent/WO2017199014A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1608587.0A 2016-05-16 2016-05-16 Treatment of opiod tolerance Ceased GB201608587D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1608587.0A GB201608587D0 (en) 2016-05-16 2016-05-16 Treatment of opiod tolerance
PCT/GB2017/051361 WO2017199014A1 (en) 2016-05-16 2017-05-16 Treatment of opioid tolerance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1608587.0A GB201608587D0 (en) 2016-05-16 2016-05-16 Treatment of opiod tolerance

Publications (1)

Publication Number Publication Date
GB201608587D0 true GB201608587D0 (en) 2016-06-29

Family

ID=56320480

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1608587.0A Ceased GB201608587D0 (en) 2016-05-16 2016-05-16 Treatment of opiod tolerance

Country Status (2)

Country Link
GB (1) GB201608587D0 (en)
WO (1) WO2017199014A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230065816A1 (en) * 2020-02-07 2023-03-02 The Reasearch Foundation For Suny Methods for preventing and reversing opioid analgesic tolerance in subjects with chronic pain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
TWI338004B (en) 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors

Also Published As

Publication number Publication date
WO2017199014A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
IL259110A (en) Treatment of osteoarthritis
IL253803B (en) Treatment of hypoparathyroidism
SG11201609652RA (en) Treatment of polybacterials infections
SMT202100115T1 (en) Combinations of fgfr- and cmet-inhibitors for the treatment of cancer
GB201608885D0 (en) Treatment
IL285882A (en) Therapeutic uses of l-4-chlorokynurenine
HUE045764T2 (en) Orvepitant for the treatment of chronic cough
PL3122349T3 (en) Compositions for the treatment of autodigestion
GB201519450D0 (en) Novel treatment
GB201607388D0 (en) Treatment of impulsivity-related disorders
IL260094A (en) Treatment of hand eczema
HUE062859T2 (en) Treatment of wastewater
IL263564B (en) Peptides for the treatment of osteoarthritis
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201617470D0 (en) Novel therapy
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201608587D0 (en) Treatment of opiod tolerance
IL267059A (en) Composition for the treatment of osteoarthritis
GB201512139D0 (en) Methods of treatment
GB201617107D0 (en) Treatment
GB201507042D0 (en) Treatment of the symptoms of osteoarthritis
GB201507040D0 (en) Treatment of the the symptoms of osteoarthritis
GB201612260D0 (en) Treatment
GB201612193D0 (en) Treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)